Explore the details of the Novo Nordisk Inc. V. Mylan Pharmaceuticals Inc. case under case number 1:25-cv-00276 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:25-cv-00276
Filing Date
Mar 10, 2025
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Novo Nordisk Inc. -
Mylan Pharmaceuticals Inc. -

Patents Involved in the Case

There is a single patent involved in this case.

Application NumberPatent Number
-US12214017B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Mar 21, 2025SO ORDERED, re (256 in 1:23-cv-00101-CFC, 7 in 1:25-cv-00276-CFC) Joint MOTION to Consolidate Cases (Case No. 25-276 into Lead Case 23-101-CFC) filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 3/21/2025. Associated Cases: 1:23-cv-00101-CFC, 1:25-cv-00276-CFC(mws) (Entered: 03/21/2025)PACER Document
Mar 7, 2025Summons Issued as to Mylan Pharmaceuticals Inc. on 3/10/2025. (slk). (Entered: 03/10/2025)PACER Document
Mar 7, 2025Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Nordisk US Holdings Inc., Corporate Parent Novo Nordisk Commercial Holdings, Inc. for Novo Nordisk Inc.; Corporate Parent Novo Holdings A/S, Corporate Parent Novo Nordisk Foundation for Novo Nordisk A/S filed by Novo Nordisk A/S, Novo Nordisk Inc. (slk) (Entered: 03/10/2025)PACER Document
Mar 7, 2025Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 12,214,017. (slk) (Entered: 03/10/2025)PACER Document
Mar 7, 2025Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: Date of Expiration of Patent: August 24, 2038.Thirty Month Stay Deadline: 6/17/2025. (slk) (Entered: 03/10/2025)PACER Document
Mar 7, 2025Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (slk). (Entered: 03/10/2025)PACER Document
Mar 7, 2025COMPLAINT against Mylan Pharmaceuticals Inc. (Filing fee $ 405, receipt number ADEDC-4631856) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1, # 2 Civil Cover Sheet)(slk). (Entered: 03/10/2025)PACER Document
Mar 10, 2025JOINT Motion and Proposed Order to Consolidate Case 25-276 into Lead Case 23-101-CFC - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) Modified on 3/11/2025 (nms). (Entered: 03/10/2025)PACER Document
Mar 10, 2025Letter to The Honorable Colm F. Connolly, from Travis J. Murray, regarding context and explanation for request to consolidate. (Murray, Travis) Modified on 3/11/2025 (nms). (Entered: 03/10/2025)PACER Document
Mar 12, 2025STANDING ORDER REGARDING BRIEFING IN ALL CASES (mws) (Entered: 03/12/2025)PACER Document
Mar 21, 2025Case associated with lead case: Create association to 1:23-cv-00101-CFC. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 23-101-CFC ONLY. (mws)PACER Document
Mar 10, 2025Remark: MDL Panel has been notified. (slk)PACER Document
Mar 12, 2025Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb)PACER Document